drugset / Trial / NCT00148330

Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study

NCT00148330

Phase 2/3 Completed 64 enrolled University of Sydney
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This open label extension will treat all the eyes of study participants with active study medication (intravitreal triamcinolone) as well as standard laser treatment where appropriate. The specific aims will be to test the following hypotheses: * That intravitreal triamcinolone for diabetic macular oedema that persists or recurs after laser treatment remains efficacious over five years * That intravitreal triamcinolone for diabetic macular oedema that persists or recurs after laser treatment retains a manageable and acceptable safety profile over five years

Timeline

Start
2005-05
Primary completion
2008-07
Completion
2008-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Triamcinolone Other / unclassified 4 mg Intravitreal